News | June 01, 2021
Marksans Pharma Q4 FY21 profit up 86%
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
7.94 crore doses were made available to the states in May 2021
Adjusted PAT declined 18.8% YoY
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
